Leidy Isenalumhe, MD, MS

Cancer Focus:
Hodgkin Lymphoma, Leukemia, Non-Hodgkin Lymphoma

Dr. Isenalumehe earned her MD from Sophie Davis School of Biomedical Education, CUNY Medical College, City College of New York (BA/MD Program) / Albany Medical College, New York and her MS degree in Clinical and Biomedical Investigation from the University of Southern California, Los Angeles. She completed a combined Internal Medicine and Pediatric Residency at NJMS-Rutgers (former: University of Medicine and Dentistry of New Jersey, Newark, where she also served as Internal Medicine-Pediatrics Chief Resident.  She completed a Pediatric Hematology-Oncology Fellowship at Children’s Hospital of Los Angeles, University of Southern California, where she also served as Chief Fellow.  She recently completed an Adult Hematology and Medical Oncology Fellowship at the University of South Florida Morsani College of Medicine and Moffitt Cancer Center.  Dr. Isenalumhe is uniquely trained in both Pediatric and Adult Hematology-Oncology.  Her clinical focus is in malignant hematology, more specifically leukemia and lymphoma in the Adolescent and Young Adult (AYA) population.  Dr. Isenalumhe’s research focus is on disparities experienced among Adolescent and Young Adult (AYA) oncology patients, particularly treatment toxicities and their effect on this unique cohort’s overall outcome. 

Education & Training

Board Certification:

• Internal Medicine - Hematology
• Pediatrics - Pediatric Hematology-Oncology
• Internal Medicine - Medical Oncology

Fellowship:

• University of Southern California - Pediatric Hematology-Oncology
• University of South Florida/H. Lee Moffitt Cancer Center and Research Institute - Hematology Oncology

Residency:

• NJMS Rutgers - Internal Medicine & Pediatrics

Medical School:

• Albany Medical College - MD

• Werner Idiaquez D, Isenalumhe LL, Hyjek EM, Sharma R, Tashkandi H, Ryder CB, Hussaini M. CD5-positive B-cell acute lymphoblastic leukemia/lymphoma with MEF2D::BCL9 mimicking aggressive mature B-cell lymphoma: a case report of a newly described entity and potential diagnostic pitfall. J Hematop. 2025 May.18(1):26. Pubmedid: 40358810.
• Lee G, Benyahia S, Syed M, Thakkar H, Reich R, Lochner J, Isenalumhe L, Hembree T, Verma N, Abdallah E. QIM25-218: Improving Quality Outcomes Through a Hospitalist-Driven Malignant Hematology Service. J Natl Compr Canc Ne. 2025 Mar.23(3.5). Pubmedid: 40154296.
• Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024 May.32(6):1031-1036. Pubmedid: 38827319. Pmcid: PMC11136690.
• Dong N, Zhang H, Song J, Mammadova J, Shah B, Saeed H, Gaballa S, Grajales-Cruz A, Isenalumhe L, Bello C, Sokol L, Pinilla J, Chavez J. B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem. 2024 Feb.5(1):285-289. Pubmedid: 38406544. Pmcid: PMC10887266.
• Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. Leuk Lymphoma. 2023 Jan.64(1):230-233. Pubmedid: 36301721.
• Azem A, Caddell R, Nelson R, Isenalumhe L, Gaballa S, Chavez J, Bello C, Pinilla J, Sokol L, Shah B, Saeed H. Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. Clin Lymphoma Myeloma Leuk. 2023 Aug.23(8):606-609. Pubmedid: 37210271.
• Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. J Natl Compr Canc Ne. 2021 Jun.19(6):733-754. Pubmedid: 34214968.
• Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
• Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
• Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020 Feb.4(3):530-538. Pubmedid: 32045474. Pmcid: PMC7013263.
• Rose A, Isenalumhe L, Van den Bergh M, Sokol L. Clonal T-cell Large Granular Lymphocytic Disorders Manifesting in Patients with HIV-1 Infection: Case Series and Review of the Literature. Mediterr J Hematol Infect Dis. 2018 Jun.10(1):e2018036. Pubmedid: 30002792. Pmcid: PMC6039084.
• Moskalewicz RL, Isenalumhe LL, Luu C, Wee CP, Nager AL. Bacteremia in nonneutropenic pediatric oncology patients with central venous catheters in the ED. Am J Emerg Med. 2017 Jan.35(1):20-24. Pubmedid: 27765482.
• Isenalumhe LL, Fridgen O, Beaupin LK, Quinn GP, Reed DR. Disparities in Adolescents and Young Adults With Cancer. Cancer Control. 2016 Oct.23(4):424-433. Pubmedid: 27842332.
• Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, Isenalumhe LL, Greco SJ, Ayer S, Bryan M, Kumar R, Ponzio NM, Rameshwar P. Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. Cancer Res. 2016 Oct.76(19):5832-5844. Pubmedid: 27569215.